Conclusion Of Non-Exclusive Discount Agreements In Accordance With §§ 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Omalizumab (R03Dx05) As Part Of A So-Called Open House Model.

AOK Rhineland-Palatinate Saarland - The health insurance company Germany has Released a tender for Conclusion Of Non-Exclusive Discount Agreements In Accordance With §§ 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Omalizumab (R03Dx05) As Part Of A So-Called Open House Model. in Pharmaceuticals. The tender was released on Jun 22, 2023.

Country - Germany

Summary - Conclusion Of Non-Exclusive Discount Agreements In Accordance With §§ 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Omalizumab (R03Dx05) As Part Of A So-Called Open House Model.

Deadline - May 31, 2025

GT reference number - 67865110

Product classification - Pharmaceutical products